⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 26, 2024CancersOpen Access

Prognostic Role of CA-125 Elimination Rate Constant (KELIM) in Patients with Advanced Epithelial Ovarian Cancer Who Received PARP Inhibitors

Ji Hyun Kim Eun Taeg Kim Se Ik Kim Eun Young Park Min Young Park Sang‐Yoon Park Myong Cheol Lim

View Full Paper

Ask AI

Bookmark

Share

Abstract

This multicenter retrospective study aimed to investigate the prognostic value of the CA-125 elimination rate constant K (KELIM) in EOC patients who received platinum-based chemotherapy followed by PARP inhibitors, in either upfront or interval treatment settings.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2024) studied this question.

synapsesocial.com/papers/68e633a8b6db6435875c505d https://doi.org/10.3390/cancers16132339

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1CA-125 KELIM as a tool to identify which patients can benefit from PARPi in high grade serous advanced ovarian cancer: A retrospective diagnostic accuracy study.2024 · 1 citations
2CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study2024 · 6 citations
3CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals2024 · 12 citations
4905 Using chemotherapy response by KELIM score in patient with BRCA-mutated high-grade serous ovarian cancer to predict response to first line olaparib maintenance therapy: an one institution experience2024
5Evaluating tumor chemosensitivity: a head-to-head comparison of the prognostic value of KELIM (modeled CA125 elimination rate constant K) and RECIST 1.1 (radiological response valuation criteria in solid tumors) in ovarian cancerOriginal Research · 2026